CLDI Insider Trading

Insider Ownership Percentage: 24.28%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $16,200.00

Calidi Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Calidi Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Calidi Biotherapeutics Share Price & Price History

Current Price: $1.36
Price Change: Price Increase of +0.01 (0.74%)
As of 02/14/2025 05:00 PM ET

This chart shows the closing price history over time for CLDI up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Calidi Biotherapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2024Allan CamaisaCEOSell10,000$1.62$16,200.0066,712View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Calidi Biotherapeutics (NYSE:CLDI)

12.53% of Calidi Biotherapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CLDI by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Calidi Biotherapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/14/2025Jane Street Group LLC33,437$38K0.0%N/A0.126%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC160,018$0.18M0.0%+304.0%0.605%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC73,448$84K0.0%N/A0.278%Search for SEC Filing on Google Icon
2/10/2025RS Crum Inc.40,463$47K0.0%N/A0.153%Search for SEC Filing on Google Icon
2/7/2025HighTower Advisors LLC102,276$0.12M0.0%N/A0.386%Search for SEC Filing on Google Icon
2/3/2025Red Wave Investments LLC80,828$93K0.0%+74.0%0.305%Search for SEC Filing on Google Icon
1/22/2025Drive Wealth Management LLC90,000$0.10M0.0%N/A0.340%Search for SEC Filing on Google Icon
1/14/2025CPR Investments Inc.101,000$0.12M0.1%+80.4%0.772%Search for SEC Filing on Google Icon
11/15/2024Red Wave Investments LLC46,461$53K0.0%-92.6%0.418%Search for SEC Filing on Google Icon
8/15/2024Delta Investment Management LLC210,230$42K0.0%+1,955.0%0.413%Search for SEC Filing on Google Icon
8/8/2024RS Crum Inc.263,470$53K0.0%+2,327.4%0.517%Search for SEC Filing on Google Icon
7/19/2024CPR Investments Inc.560,000$0.11M0.1%+700.0%11.002%Search for SEC Filing on Google Icon
5/16/2024Apollo Management Holdings L.P.125,000$71K0.0%N/A0.352%Search for SEC Filing on Google Icon
5/15/2024Magnetar Financial LLC63,132$36K0.0%N/A0.178%Search for SEC Filing on Google Icon
5/14/2024Evermay Wealth Management LLC63,416$36K0.0%N/A0.178%Search for SEC Filing on Google Icon
4/23/2024Spectrum Asset Management Inc. NB CA 166,494$94K0.0%N/A0.468%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Calidi Biotherapeutics logo
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Read More on Calidi Biotherapeutics

Today's Range

Now: $1.36
Low: $1.25
High: $1.39

50 Day Range

MA: $1.23
Low: $0.63
High: $1.92

52 Week Range

Now: $1.36
Low: $0.58
High: $16.80

Volume

1,071,712 shs

Average Volume

2,454,461 shs

Market Capitalization

$35.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Who are the company insiders with the largest holdings of Calidi Biotherapeutics?

Calidi Biotherapeutics' top insider investors include:
  1. Allan Camaisa (CEO)
Learn More about top insider investors at Calidi Biotherapeutics.

Who are the major institutional investors of Calidi Biotherapeutics?

Calidi Biotherapeutics' top institutional investors include:
  1. Geode Capital Management LLC — 0.60%
  2. HighTower Advisors LLC — 0.39%
  3. CPR Investments Inc. — 0.77%
  4. Drive Wealth Management LLC — 0.34%
  5. Red Wave Investments LLC — 0.31%
  6. Virtu Financial LLC — 0.28%
Learn More about top institutional investors of Calidi Biotherapeutics stock.

Which major investors are buying Calidi Biotherapeutics stock?

Within the last quarter, CLDI stock was purchased by institutional investors including:
  1. Geode Capital Management LLC
  2. HighTower Advisors LLC
  3. Drive Wealth Management LLC
  4. Virtu Financial LLC
  5. CPR Investments Inc.
  6. RS Crum Inc.
  7. Red Wave Investments LLC
  8. Jane Street Group LLC